Ahead of the summer vacation season, Dongkuk Pharmaceutical has introduced a dermatitis treatment 'Sensekin Cream' with a ...

Skin is more than a reflection in the mirror it’s the largest organ of your body, toiling away to shield you from the outside ...

Examples include pimecrolimus (Elidel), which is a cream, and crisaborole (Eucrisa) and tacrolimus (Protopic), which are ointments. You should only use these for a short time if other treatments ...

Incyte (Nasdaq: INCY) today announced that the U.S. Food and Drug Administration (FDA) has extended the review period for the ...

cream 0.15 percent for adults and children ages 6 or older with mild to moderate atopic dermatitis, the most common type of eczema. A once-daily topical treatment, Zoryve works quickly and with ...

Ruxolitinib 0.75% cream and ruxolitinib 1.5% cream are effective and well-tolerated in children aged 2 to 11 years with atopic dermatitis.

cream 0.15% for the treatment of mild to moderate atopic dermatitis in adults and children down to age 6 in the United States. ZORYVE is a once-daily, steroid-free cream that provides rapid ...

Once-daily roflumilast cream at 0.15% improved symptoms of atopic dermatitis (AD ... roflumilast could help improve treatment adherence in a population group that often has trouble continuing ...

demonstrates that initiating ruxolitinib cream therapy for atopic dermatitis (AD) significantly reduced patients’ reliance on other topical treatments, oral corticosteroids, and biologics in ...

For some people, using mild soaps and avoiding heavy skin creams and fluorinated toothpaste may help. It may take a few weeks to months for perioral dermatitis to clear up. Treatment by a ...

Perioral dermatitis is a skin condition that causes a rash around the mouth. It may also occur around the eyes or nose, but this is much less common. Treatments may include certain creams ...

About INTEGUMENT-OLEThe “INterventional Trial EvaluatinG roflUMilast cream for the treatmENt of aTopic dermatitis” Open Label Extension (INTEGUMENT-OLE) was a Phase 3, multicenter, open-label ...